MarketPeel
Insider Trading Intelligence
JH

John P. Hamill

APRE
SRVP/CFO/PRIN FIN & ACCT OFCR · APREA THERAPEUTICS, INC. · CIK 0001716213
FILING MIX · LIFETIME100%/0%
BUYS
20
SELLS
0
TOTAL VALUE
$49.8K
COMPANIES
1
ACTIVE SINCE
Jan 2023
HOLDINGS NOW
30,978
AVG SELL PX
TRADE KIND
SHOWING 20 / 20
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
11 backtested trades · 8 horizons · 18 pending
Forward-return performance of every backtestable P/S trade by John P. Hamill, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d11+45.45%+14.10%+0.29%+13.81%+2.13%
14d11+81.82%+13.35%+1.55%+11.80%+7.66%
30d11+100.00%+11.19%+2.40%+8.79%+3.57%
60d11+63.64%+5.20%+0.29%+1.18%-0.55%
90d11+54.55%+3.46%+4.25%-0.79%-7.37%
180d11(4 pending)+0.00%-33.37%+2.31%-35.68%-34.30%
1y11(6 pending)+0.00%-52.22%+10.44%-62.66%-65.45%
2y11(8 pending)+0.00%-86.74%+30.39%-117.13%-117.13%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
APRE · 30,978 shares · as of Mar 31, 2026
0134,940269,879404,819539,758202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 20 buys / 0 sellsCOVERAGE · 13 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
APRE
APREA THERAPEUTICS, INC.
PURCHASE
SrVP/CFO/Prin Fin & Acct Ofcr
30,978$0.81$25.0K30,978Mar 31, 2026Apr 1, 2026View →
APRE
APREA THERAPEUTICS, INC.
PURCHASE
SrVP/CFO/Prin Fin & Acct Ofcr
30,97830,978Mar 31, 2026Apr 1, 2026View →
APRE
APREA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
40,38040,380Mar 12, 2026Mar 16, 2026View →
APRE
APREA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
10,09543,528Mar 12, 2026Mar 16, 2026View →
APRE
APREA THERAPEUTICS, INC.
PURCHASE
SrVP/CFO/Prin Fin & Acct Ofcr
5,700$0.89$5.1K33,433Jan 30, 2026Feb 2, 2026View →
APRE
APREA THERAPEUTICS, INC.
PURCHASE
SrVP/CFO/Prin Fin & Acct Ofcr
5,7005,700Jan 30, 2026Feb 2, 2026View →
APRE
APREA THERAPEUTICS, INC.
PURCHASE
SrVP/CFO/Prin Fin & Acct Ofcr
5,0005,000Dec 10, 2025Dec 11, 2025View →
APRE
APREA THERAPEUTICS, INC.
PURCHASE
SrVP/CFO/Prin Fin & Acct Ofcr
5,000$1.17$5.8K27,733Dec 10, 2025Dec 11, 2025View →
APRE
APREA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
3,36522,733Mar 27, 2025Mar 31, 2025View →
APRE
APREA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
13,46013,460Mar 27, 2025Mar 31, 2025View →
APRE
APREA THERAPEUTICS, INC.
PURCHASE
SrVP/CFO/Prin Fin & Acct Ofcr
50$2.46$12319,368Oct 11, 2024Oct 16, 2024View →
APRE
APREA THERAPEUTICS, INC.
PURCHASE
SrVP/CFO/Prin Fin & Acct Ofcr
450$2.61$1.2K19,318Oct 10, 2024Oct 15, 2024View →
APRE
APREA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
3,36518,868Mar 28, 2024Mar 28, 2024View →
APRE
APREA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
13,46013,460Mar 28, 2024Mar 28, 2024View →
APRE
APREA THERAPEUTICS, INC.
PURCHASE
SrVP/CFO/Prin Fin & Acct Ofcr
505505Mar 13, 2024Mar 14, 2024View →
APRE
APREA THERAPEUTICS, INC.
PURCHASE
SrVP/CFO/Prin Fin & Acct Ofcr
1,010$7.29$7.4K15,503Mar 13, 2024Mar 14, 2024View →
APRE
APREA THERAPEUTICS, INC.
PURCHASE
SrVP/CFO/Prin Fin & Acct Ofcr
505505Mar 13, 2024Mar 14, 2024View →
APRE
APREA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
1,000$5.25$5.3K14,493Feb 27, 2023Feb 27, 2023View →
APRE
APREA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
269,879269,879Jan 30, 2023Jan 30, 2023View →
APRE
APREA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
539,758539,758Jan 30, 2023Jan 30, 2023View →
Other insiders · APRE
Loading peer insiders…
About this filer
CIK 0001716213
ROLE
SrVP/CFO/Prin Fin & Acct Ofcr
PRIMARY
APRE
COMPANIES
1
ACTIVE SINCE
Jan 2023
MARKETPEEL · /INSIDER/0001716213DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback